Cargando…
A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
Autores principales: | Qaqish, R, van Wyk, J, King, MS |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113062/ http://dx.doi.org/10.1186/1758-2652-13-S4-P58 |
Ejemplares similares
-
Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Publicado: (2015) -
Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014) -
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010) -
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010) -
CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)